WuXi STA, a CRDMO, began the groundbreaking process for its new 190-acre pharmaceutical manufacturing campus in Middletown, DE. The site will be WuXi STA’s second facility in the U.S., offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world, according to company officials.

The WuXi STA Middletown site is located in the Middletown Business Center, and the new facility is expected to create approximately 500 full-time jobs by 2026.

EwingCole and Genesis AEC are the architectural firms that designed the new facility project, a rendering of which is shown here. [EwingCole]
Phase I of the new campus will provide formulation development, clinical, and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.

WuXi STA has 12 sites across the U.S., Europe, and Asia that offer a range of services. Together with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China), and Shanghai, this new facility will further enhance the company’s global drug production capacity and capabilities, said Minzhang Chen, PhD, co-CEO of WuXi AppTec and CEO of WuXi STA.

“I would like to thank our federal, state and local partners in Delaware for their continued support in the establishment of this site,” continued Chen. “WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated Contract Research, Development, and Manufacturing Organization  platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.”

The WuXi STA Middletown facility is expected to begin operations in 2025.